SGI-7079
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206483

CAS#: 1239875-86-5

Description: SGI-7079 is a potent and selective Axl inhibitor with potential anticancer activity. SGI-7079 effectively inhibited Axl activation in the presence of exogenous Gas6 ligand. SGI-7079 inhibited tumor growth in a dose dependent manner. Axl is a potential therapeutic target for overcoming EGFR inhibitor resistance.

Chemical Structure

img
SGI-7079
CAS# 1239875-86-5
Handing Instruction

Theoretical Analysis

MedKoo Cat#: 206483
Name: SGI-7079
CAS#: 1239875-86-5
Chemical Formula: C26H26FN7
Exact Mass: 455.22337
Molecular Weight: 455.5414
Elemental Analysis: C, 68.55; H, 5.75; F, 4.17; N, 21.52

Size Price Shipping out time Quantity
100mg USD 850 2 Weeks
200mg USD 1350 2 Weeks
500mg USD 2150 2 Weeks
1g USD 3150 2 Weeks
2g USD 4250 2 Weeks
Inquire bulk and customized quantity
Pricing updated 2021-03-01. Prices are subject to change without notice.

SGI-7079, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Synonym: SGI-7079; SGI 7079; SGI7079.

IUPAC/Chemical Name: 2-(3-(2-((3-fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile

InChi Key: BCFKACXAIBEPKR-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H26FN7/c1-17-16-29-25-23(17)24(19-5-3-4-18(14-19)8-9-28)31-26(32-25)30-20-6-7-22(21(27)15-20)34-12-10-33(2)11-13-34/h3-7,14-16H,8,10-13H2,1-2H3,(H2,29,30,31,32)

SMILES Code: N#CCC1=CC=CC(C2=C3C(NC=C3C)=NC(NC4=CC=C(N5CCN(C)CC5)C(F)=C4)=N2)=C1

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 455.5414 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM,
Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the
development and progression of inflammatory breast cancer through activation of
Axl kinase. Cancer Res. 2013 Nov 1;73(21):6516-25. doi:
10.1158/0008-5472.CAN-13-0967. Epub 2013 Sep 6. PubMed PMID: 24014597.

2: Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri
U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL,
Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS,
Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN,
Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal
transition gene signature predicts resistance to EGFR and PI3K inhibitors and
identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558.
Epub 2012 Oct 22. PubMed PMID: 23091115; PubMed Central PMCID: PMC3567921.

img

SGI-7079

100mg / USD 850